ArticleJournal of clinical medicine2021
The Two-Step Treatment for Giant Hepatic Hemangiomas.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate.The Korean journal of internal medicine · 2023Trial
- Minimally invasive versus open liver resection for benign disease: analysis of textbook outcomes according to difficulty of resections and role of the robotic approach.Surgical endoscopy · 2026Article
- Robotic versus laparoscopic liver resection for intrahepatic cholangiocarcinoma in elderly patients: a multicentre propensity-weighted analysis.Surgical endoscopy · 2026Article
- Laparoscopic right hepatectomy for giant hepatic hemangioma with endoscopic nasobiliary drainage-guided biliary confirmation.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Safety and feasibility of laparoscopic resection for giant hepatic hemangiomas: a retrospective cohort study.BMC surgery · 2026Article
- Successful long-term results (> 5 years) of superselective transarterial chemoembolization in symptomatic/enlarging liver hemangiomas: a paradigm shift at a hepatopancreatobiliary surgery unit.Frontiers in medicine · 2026Article
- A novel and effective strategy for the treatment of large hepatic hemangioma: combining preoperative embolization with laparoscopic-assisted and ultrasound-guided ablation.World journal of surgical oncology · 2025Article
- Hepatic Hemangioma: Review of Imaging and Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Risk factor analysis of conversion in laparoscopic liver resection for intrahepatic cholangiocarcinoma.Surgical endoscopy · 2024Article
- Article
- Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.BMC pediatrics · 2024Article
- Transarterial embolization for rare spontaneous subacute intratumoral hemorrhage of hepatic hemangioma: a case report and literature review.Translational cancer research · 2022Article
- Editorial of Special Issue "Embolization Techniques: State of the Art and Future Perspectives".Journal of clinical medicine · 2022Article
- Medium and Long-Term Outcome of Superselective Transcatheter Arterial Embolization with Lipiodol-Bleomycin Emulsion for Giant Hepatic Hemangiomas: Results in 241 Patients.Journal of clinical medicine · 2022Article
- Risk factors for hypercoagulability after laparoscopic hepatic haemangioma resection.Journal of minimal access surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study is to analyze the feasibility and the impact of a two-step approach in the treatment of giant hemangiomas (GH) i.e., exceeding 10 cm in maximum diameter, consisting of transarterial embolization (TAE) followed by laparoscopic liver resection (LLR). Ten patients with 11 GH were treated with TAE and subsequent LLR between 2017 and 2020 (Group A). A matched cohort of 10 patients with GH treated with upfront LLR between 2014 and 2017 was identified for comparison (Group B). Data were analyzed regarding intraoperative and postoperative outcomes, including successful completion of LLR, morbidity, and mortality. Successful microparticle embolization of the GH-feeding arteries was performed in all patients in group A. In three cases a liquid embolic agent (Squid-18) was also injected to obtain complete embolization. No complications were observed after TAE. Successful surgery was performed after a mean time interval of 2.2 days from TAE without any case of conversion to laparotomy. Statistically significant differences between group A and group B were found in intraoperative blood loss (250 ± 200 vs. 400 ± 300 mL,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.